JP7102388B2 - 単環式ヘテロアリール置換化合物 - Google Patents

単環式ヘテロアリール置換化合物 Download PDF

Info

Publication number
JP7102388B2
JP7102388B2 JP2019501720A JP2019501720A JP7102388B2 JP 7102388 B2 JP7102388 B2 JP 7102388B2 JP 2019501720 A JP2019501720 A JP 2019501720A JP 2019501720 A JP2019501720 A JP 2019501720A JP 7102388 B2 JP7102388 B2 JP 7102388B2
Authority
JP
Japan
Prior art keywords
methylquinoxaline
difluoromethoxy
thiazole
mmol
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019501720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521153A (ja
JP2019521153A5 (enExample
Inventor
ジェレミー・エム・リヒター
シャオジュン・ジャン
エルドン・スコット・プリーストリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019521153A publication Critical patent/JP2019521153A/ja
Publication of JP2019521153A5 publication Critical patent/JP2019521153A5/ja
Application granted granted Critical
Publication of JP7102388B2 publication Critical patent/JP7102388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019501720A 2016-07-14 2017-07-13 単環式ヘテロアリール置換化合物 Active JP7102388B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362081P 2016-07-14 2016-07-14
US62/362,081 2016-07-14
PCT/US2017/041873 WO2018013772A1 (en) 2016-07-14 2017-07-13 Monocyclic heteroaryl substituted compounds

Publications (3)

Publication Number Publication Date
JP2019521153A JP2019521153A (ja) 2019-07-25
JP2019521153A5 JP2019521153A5 (enExample) 2020-08-06
JP7102388B2 true JP7102388B2 (ja) 2022-07-19

Family

ID=59384257

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019501720A Active JP7102388B2 (ja) 2016-07-14 2017-07-13 単環式ヘテロアリール置換化合物

Country Status (7)

Country Link
US (1) US10815224B2 (enExample)
EP (1) EP3484874B1 (enExample)
JP (1) JP7102388B2 (enExample)
KR (1) KR102492715B1 (enExample)
CN (1) CN109689642B (enExample)
ES (1) ES2805030T3 (enExample)
WO (1) WO2018013772A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10730868B2 (en) 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
EP3484894B1 (en) 2016-07-14 2020-08-19 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors
ES2823180T3 (es) 2016-07-14 2021-05-06 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos con heteroarilo
JP7298711B2 (ja) 2019-12-04 2023-06-27 日本電気株式会社 体調異常判定システム、体調異常判定システムの作動方法、及びコンピュータプログラム
CN111440146B (zh) * 2020-05-15 2022-10-21 中国药科大学 一种具有par4拮抗活性的苯并三嗪类化合物及其应用
CN116041341B (zh) * 2022-11-24 2025-02-28 中国药科大学 一种喹唑啉类par4拮抗剂及其医药应用
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508113A (ja) 2002-11-12 2006-03-09 ファイザー・プロダクツ・インク キノリン誘導体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472406A (en) * 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo [ij]quinolizine-2-carboxylic acids and derivatives
US4567269A (en) * 1982-11-12 1986-01-28 Riker Laboratories, Inc. Intermediates for the preparation of 6,7-dihydro-8-(imidazol-1-yl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acids
US4567186A (en) * 1985-01-14 1986-01-28 Sterling Drug Inc. 5-Heteryl-1,6-naphthyridin-2(1H)-ones, cardiotonic use thereof and intermediates therefor
EP0224823A3 (de) * 1985-11-26 1988-02-10 BASF Aktiengesellschaft Chinolinderivate und ihre Verwendung zur Bekämpfung von unerwümschtem Pflanzenwachstum
DE3541722A1 (de) * 1985-11-26 1987-05-27 Basf Ag Chinolinderivate und ihre verwendung zur bekaempfung von unerwuenschtem pflanzenwachstum
KR900004213A (ko) * 1988-08-12 1990-03-27 최근선 쌍 방향 송수신의 원격 제어 시스템
US5110347A (en) * 1990-11-26 1992-05-05 E. I Du Pont De Nemours And Company Substituted fused heterocyclic herbicides
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
US6245760B1 (en) * 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6387942B2 (en) 2000-06-19 2002-05-14 Yung Shin Pharmaceutical Ind. Co. Ltd Method of treating disorders related to protease-activated receptors-induced cell activation
US6894062B1 (en) * 2002-11-12 2005-05-17 Pfizer Inc. Quinoline derivatives
US20080015193A1 (en) 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
TW200902008A (en) * 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
WO2012054874A1 (en) 2010-10-22 2012-04-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CN102827073A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013130660A1 (en) 2012-02-28 2013-09-06 Amgen Inc. Amides as pim inhibitors
KR20150003766A (ko) 2012-04-26 2015-01-09 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체
ES2640916T3 (es) 2012-04-26 2017-11-07 Bristol-Myers Squibb Company Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor 4 activados por proteasa (PAR4) para tratar agregación plaquetaria
SG11201406759YA (en) 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
CA2922542A1 (en) 2013-11-22 2015-05-28 University Of Kentucky Research Foundation Arylquinoline and analog compounds and use thereof to treat cancer
EP3262053B1 (en) 2015-02-26 2022-10-05 Université de Montréal Imidazothiadiazole compounds as par4-inhibitors
EP3328839A1 (en) * 2015-07-30 2018-06-06 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
ES2823180T3 (es) * 2016-07-14 2021-05-06 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos con heteroarilo
US10730868B2 (en) * 2016-07-14 2020-08-04 Bristol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
EP3484894B1 (en) 2016-07-14 2020-08-19 Bristol-Myers Squibb Company Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as par4 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508113A (ja) 2002-11-12 2006-03-09 ファイザー・プロダクツ・インク キノリン誘導体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALABASTER, C. T. et al.，2(1H)-QUINOLINONES WITH CARDIAC STIMULANT ACTIVITY. 1. SYNTHESIS AND BIOLOGICAL ACTIVITIES OF (SIX-MEMBERED HETEROARYL)-SUBSTITUTED DERIVATIVES，Journal of Medicinal Chemistry，1988年，Vol.31，No.10，p.2048-2056，http://dx.doi.org/10.1021/jm00118a034
Kuang, Rongze et al.，Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors，Bioorganic & Medicinal Chemistry Letters ，2007年，Vol.17，No.18，p.5150-5154

Also Published As

Publication number Publication date
KR102492715B1 (ko) 2023-01-26
CN109689642B (zh) 2022-04-12
WO2018013772A1 (en) 2018-01-18
CN109689642A (zh) 2019-04-26
EP3484874B1 (en) 2020-04-29
EP3484874A1 (en) 2019-05-22
KR20190026905A (ko) 2019-03-13
JP2019521153A (ja) 2019-07-25
ES2805030T3 (es) 2021-02-10
US20190248771A1 (en) 2019-08-15
US10815224B2 (en) 2020-10-27

Similar Documents

Publication Publication Date Title
KR102492715B1 (ko) 모노시클릭 헤테로아릴 치환된 화합물
EP2855489B1 (en) Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
JP6181744B2 (ja) 血小板凝集を治療するためのプロテアーゼ活性化受容体４（ｐａｒ４）阻害剤としてのイミダゾチアジアゾール誘導体
JP6990228B2 (ja) 二環式ヘテロアリール置換の化合物
KR102500570B1 (ko) 삼환식 화합물, 이의 제조방법 및 용도
CN112204023A (zh) 因子XIIa抑制剂
CN104411713A (zh) Par4激动剂肽
CN111315380A (zh) 凋亡信号调节激酶抑制剂及其用途
JP2018525371A (ja) アリール置換された二環式ヘテロアリール化合物
JP2023518262A (ja) Ｐｈｄ阻害剤化合物、組成物、及び使用
JP2025517407A (ja) 線維性疾患治療用アゾロ化合物
EP3262052A1 (en) Benzothiazole and benzothiophne compounds
CN116969918A (zh) 氟取代的吡啶酮类衍生物及其药物组合物、制备方法和用途
CN110343089A (zh) 苯并咪唑类衍生物及其药学用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220318

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220706

R150 Certificate of patent or registration of utility model

Ref document number: 7102388

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250